The Claim
Local perfusion of glucagon and glucagon-like peptide-1-(7-36) amide at a concentration of 10⁻⁶ mol/L does not significantly alter lipolysis rates or local blood flow in human subcutaneous abdominal adipose tissue or skeletal muscle during in vivo microdialysis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When glucagon and glucagon-like peptide-1-(7-36) amide are delivered locally at a concentration of 10⁻⁶ mol/L to fat and muscle tissue under the skin in healthy people, there is no measurable change in fat breakdown or blood flow in those tissues.
See the scientific wording
Local perfusion of glucagon and glucagon-like peptide-1-(7-36) amide at a concentration of 10⁻⁶ mol/L does not significantly alter lipolysis rates or local blood flow in human subcutaneous abdominal adipose tissue or skeletal muscle during in vivo microdialysis in nine healthy individuals, as measured by dialysate glycerol and ethanol ratio.
When glucagon and GLP-1 are present at high concentrations near fat and muscle tissue, they do not trigger fat breakdown or change blood flow because the cells in those tissues do not respond to them with the right signals to start breaking down fat or opening blood vessels.
What the research says
1 studyScientists tested if two hormones, glucagon and GLP-1, make fat break down or increase blood flow in fat and muscle tissue. They found they didn’t — even at a high dose. So the claim that they don’t affect fat breakdown is supported.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.